Zydus Lifesciences has reported a surprising Q2 FY27 performance. Revenue increased nearly 29%, but profit declined almost 27%. The company sold significantly more medicines, yet earned considerably less profit. What explains this unusual difference?

Consolidated revenue reached ₹7,909.6 crore, compared with ₹6,123.2 crore in the same quarter last year. This strong growth shows that demand remained healthy across several of Zydus Lifesciences’ major businesses.

However, consolidated net profit declined 26.6% to ₹925.5 crore from approximately ₹1,261 crore last year. Compared with the June quarter, profit also declined 3.6%, suggesting that the pressure was not limited to the annual comparison.

The bigger concern becomes clear when we examine operating earnings. EBITDA declined 6% to ₹1,894.5 crore, even though revenue increased sharply. EBITDA measures earnings before interest, tax, depreciation and amortisation.

The EBITDA margin dropped from 32.9% last year to approximately 24% this quarter. In simple terms, Zydus earned around ₹24 in operating profit from every ₹100 of revenue, compared with nearly ₹33 a year earlier.

But why did profitability weaken when sales were growing? Total expenses increased much faster than revenue, with higher research spending, employee costs and other operating expenses putting pressure on earnings.

Research and development spending reached ₹657.3 crore, representing 8.3% of quarterly revenue. This investment supports new medicines and future product launches, but it also reduces the profit available today.

Depreciation expenses also increased sharply, approximately doubling from the previous year. Finance costs rose around 85%, creating additional pressure below the operating profit level.

There was another important comparison with management’s earlier expectations. Zydus had indicated strong double digit revenue growth for FY27, while the September quarter delivered 29.2% growth, comfortably exceeding that annual growth pace.

However, management’s operating margin expectation of above 24% was more challenging. The reported EBITDA margin stood at approximately 24%, leaving little room above the company’s earlier profitability objective.

North America remained the largest contributor to revenue. The formulations business generated ₹3,315 crore, representing growth of approximately 21% from last year and 7% compared with the previous quarter.

This performance was supported by higher sales volumes, new generic medicine launches and the expansion of specialty products. North America accounted for approximately 42% of consolidated quarterly revenue.

Zydus also reported that branded products represented 16% of its United States sales. This is important because the company is gradually expanding beyond traditional generic medicines into more specialised treatments.

India delivered another encouraging performance. Formulations revenue increased 18% to ₹1,884 crore, supported by strong demand across chronic disease treatments and other established medicine categories.

Within the Indian business, branded formulations grew 19%, outperforming the broader pharmaceutical market according to management. The company also reported increasing demand across its chronic therapy portfolio.

International markets outside India and North America contributed ₹1,001 crore in revenue, representing growth of approximately 33%. This indicates that the company’s expansion is not dependent on a single geography.

The consumer wellness business also delivered strong growth, with reported revenue increasing 76% year on year. This helped diversify the company’s revenue base beyond prescription medicines.

Meanwhile, Zydus continued investing in its future medicine pipeline. The US FDA accepted for review the application for its pembrolizumab biosimilar, a proposed alternative to an established cancer treatment. Regulatory acceptance for review does not mean the medicine has received final approval.

The company also highlighted progress involving Saroglitazar, an internally discovered medicine being developed for international markets. These projects could become important future opportunities, although their commercial success depends on regulatory decisions and market adoption.

Another area requiring attention is regulatory compliance. US FDA inspections at two manufacturing facilities resulted in observations that Zydus said it was addressing. Timely resolution will be important for maintaining confidence in its manufacturing operations.

The stock market reacted negatively to the earnings announcement. Zydus Lifesciences shares declined around 4% during trading on November 4, as investors weighed the sharp profit decline against the company’s strong revenue growth.

The central question now is whether Zydus can turn higher sales into stronger earnings. Its India, North America and international businesses are growing, but rising costs and lower margins have weakened profitability. Future results will reveal whether operating margins can recover while the company continues investing in new products and expansion.